Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial
- Investigate the effectiveness of flecainide in the management of neuropathic pain.
OUTLINE: Patients are given a brief pain inventory (BPI) form to assess their pain upon
enrollment in the study. Following a 7 day stabilization period, flecainide is administered.
One capsule of flecainide is given twice a day on days 8-10, two capsules are given twice a
day on days 11-14 and three capsules are given twice a day on days 15-21. BPI forms are
completed on days 8, 15 and 22 to assess neuropathic pain.
PROJECTED ACCRUAL: A total of 7-20 patients will be accrued for this study.
Primary Purpose: Supportive Care
Charles F. Von Gunten, MD, PhD
Robert H. Lurie Cancer Center
United States: Food and Drug Administration
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|
|CCOP - Iowa Oncology Research Association||Des Moines, Iowa 50309-1016|
|CCOP - Kalamazoo||Kalamazoo, Michigan 49007-3731|
|CCOP - Cedar Rapids Oncology Project||Cedar Rapids, Iowa 52403-1206|
|CCOP - Sioux Community Cancer Consortium||Sioux Falls, South Dakota 57105-1080|
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|